InvestorsHub Logo
Followers 1
Posts 121
Boards Moderated 0
Alias Born 02/28/2013

Re: None

Thursday, 02/15/2018 12:47:44 AM

Thursday, February 15, 2018 12:47:44 AM

Post# of 45197
A blast from the past (2016)
"Having demonstrated proof of principle and target engagement, the Company has concluded that further development of CX1739 to determine its potential efficacy in the appropriate clinical indications is warranted, and future studies are being designed and planned."

Beggars believe, with the opioid epidemic this never garnered more attention?

Could this be combined with an opioid to make, for lack of better words, a maximum strength pain relief medication?

Ideas are like an arse. Everyone has one.
Peace.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News